Supplemental Table 1. Patient characteristics by study site

	PHHS (n=31) n (%)	CUH (n=145) n (%)	*P* value
Age (year)*	59 (51-64)	64 (57-69)	**0.008**
Male	25 (80.6)	105 (72.4)	0.344
Race			
Caucasian	3 (9.7)	119 (82.1)	**<0.001**
Non-Caucasian	28 (90.3)	26 (17.9)	
Ever smoker	16 (51.6)	64 (44.1)	0.448
Histological subtype			
ccRCC	28 (90.3)	121 (83.4)	0.335
Non-ccRCC	3 (9.7)	24 (16.6)	
Nephrectomy	23 (74.2)	125 (86.2)	0.097
Previous radiation therapy	15 (48.4)	89 (61.4)	0.182
Prior systemic therapies	26 (83.9)	115 (79.3)	0.564
IMDC score			
Favorable	4 (12.9)	28 (19.3)	0.159
Intermediate	17 (54.8)	79 (54.5)	
Poor	10 (32.3)	27 (18.6)	
Missing	0 (0)	11 (7.6)	
Initial immunotherapy regimen			
Nivolumab	25 (80.6)	108 (74.5)	0.469
Nivolumab+Ipilimumab	6 (19.4)	37 (25.5)	
Any exposure to Ipilimumab	7 (22.6)	77 (53.1)	**0.002**
Non-colitis irAEs	6 (19.4)	67 (46.2)	**0.006**
Exposure to PPIs	15 (48.4)	89 (61.4)	0.182
Colitis of any etiology	5 (16.1)	22 (15.2)	0.893
Median follow up (month)	29.0	27.0	0.55

Data are shown as frequencies (percentages) unless otherwise indicated. ccRCC: clear cell renal cell carcinoma, CUH: Clements University Hospital, ICI: immune checkpoint inhibitor, IMDC: international metastatic renal cell carcinoma database consortium, irAE: immune-related adverse event, PHHS: Parkland Health & Hospital System, PPI: proton pump inhibitor. *P* values were calculated by comparing patients at PHHS vs CUH. *Data are shown as medians (interquartile ranges).

356

357

358